Evotec Acquires Global All Product ChemAxon License and Announces Multiple Implementations Across Informatics Platform

/PRNewswire/ -- Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30;
 Evotec) and ChemAxon, a software solutions provider for chemistry today
 announced Evotec's licensing of ChemAxon's complete product line, the
 successful implementation of selected ChemAxon toolkits and ongoing works
 to roll out further capabilities across Evotec's informatics network.
     Through the acquisition of ChemAxon's JChem platform, Evotec has built
 state of the art applications enabling it's scientists to perform and share
 key drug discovery and optimisation processes across all facilities,
 directly from their workbench.
     "Evotec are heavy users of Chemaxon's JChem products, and have
 integrated them into many of the advanced drug discovery software tools
 that we have developed internally. JChem tools allow us to develop highly
 intuitive desktop software available to all our scientists. The close
 working relationship with ChemAxon has been invaluable during our
 application development work," said Alistair Sedwell (IT Applications Team
 Leader), Evotec (UK) Ltd
     "Working with Evotec has been rewarding and has enabled us to support
 all of our clients with more relevant, accurate and powerful
 functionalities. We enjoy and look forward to continuing this
 collaboration," commented Ferenc Csizmadia, CEO Of ChemAxon.
     About ChemAxon
     ChemAxon is a leader in providing cheminformatics software development
 platforms and applications for the biotechnology, pharmaceutical and
 agrochemical industries. With core capabilities for structure visualization
 and management, property prediction, virtual synthesis, screening and drug
 design, ChemAxon focuses upon active interaction with users and software
 portability to create powerful, cost effective cross platform solutions and
 programming interfaces to power modern cheminformatics and chemical
 communication. For more information please visit www.chemaxon.com
     About Evotec AG
     Evotec is a leader in the discovery and development of novel small
 molecule drugs. Both through its own discovery programmes and through
 contract research partnerships, the Company is providing highest quality
 research results to its partners in the pharmaceutical and biotechnology
 industries.
     In proprietary projects, Evotec specialises in finding new treatments
 for diseases of the central nervous system (CNS). Evotec has three Phase I
 clinical programmes: EVT 201, a GABAA modulator for the treatment of
 insomnia, EVT 101, a subtype selective NMDA receptor antagonist for the
 treatment of Alzheimer's disease and EVT 301, a selective and reversible
 inhibitor of MAO-B for the treatment of Alzheimer's disease.
     In contract research, Evotec has established itself as the partner of
 choice for pharmaceutical and biotechnology companies worldwide. The
 Company provides innovative and often integrated solutions from drug target
 to clinic through an unmatched range of capabilities, including early stage
 assay development and screening through to medicinal chemistry and drug
 manufacturing.
     In 2005, Evotec has generated sales of EUR 80 million with
 approximately 600 people located in Hamburg, Germany and near Oxford and in
 Glasgow, UK.
     www.evotec.com
 
 

SOURCE ChemAxon Ltd.